3/10/2005 Novalar Pharmaceuticals Inc., a company specializing in dental anesthesia pharmaceuticals, has closed a $27 million Series C funding round. Novalar will use the new financing to support clinical trials and the commercial launch of its NV-101 compound, a local dental anesthesia designed to reduce the numbness time of novocaine. With the closing of this financing, Novalar has raised about $35 million since the company's inception in 2000.
